GLP-1 Market
LLY $1145.85 ▼ -1.0% NVO $37.74 ▼ -0.4% PFE $28.20 ▼ -1.1% VKTX $31.18 ▼ -4.3% KLRA $11.04 ▼ -3.3% GPCR $29.70 ▼ -5.0% RHHBY $51.91 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Brenipatide

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
13 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

13 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 1, 2026

Find a Clinical Trial Near Me

See recruiting studies for Brenipatide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07165002

    A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

    Not yet reported Eli Lilly and Company 32 participants Est. completion 2026-11 3 sites Stand-alone
    Other conditions: Healthy, Hepatic Insufficiency
    View official trial listing →
  • Recruiting NCT NCT07219173

    A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma

    Not yet reported Eli Lilly and Company 531 participants Est. completion 2028-06 121 sites Stand-alone
    Other conditions: Asthma
    View official trial listing →
  • Recruiting NCT NCT07219953

    A Study of Brenipatide in Participants With Alcohol Use Disorder

    Not yet reported Eli Lilly and Company 1100 participants Est. completion 2028-04 116 sites Stand-alone
    Alcohol use disorder
    View official trial listing →
  • Recruiting NCT NCT07219966

    A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder

    Not yet reported Eli Lilly and Company 1100 participants Est. completion 2028-04 117 sites Stand-alone
    Alcohol use disorder
    View official trial listing →
  • Recruiting NCT NCT07223840

    A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

    Not yet reported Eli Lilly and Company 222 participants Est. completion 2027-02 29 sites Stand-alone
    Other conditions: Smoking
    View official trial listing →
  • Recruiting NCT NCT07286175

    A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

    Not yet reported Eli Lilly and Company 400 participants Est. completion 2027-11 87 sites Stand-alone
    Other conditions: Bipolar Disorder
    View official trial listing →
  • Recruiting NCT NCT07410507

    A Study of Brenipatide in Adult Participants With Schizophrenia

    Not yet reported Eli Lilly and Company 450 participants Est. completion 2027-11 101 sites Stand-alone
    Other conditions: Schizophrenia
    View official trial listing →
  • Recruiting NCT NCT07412756

    A Study of Brenipatide in Adult Participants With Major Depressive Disorder

    Not yet reported Eli Lilly and Company 1000 participants Est. completion 2028-02 179 sites Stand-alone
    Other conditions: Depressive Disorder, Major
    View official trial listing →
  • Recruiting NCT NCT07420283

    A Study of Brenipatide in Participants With Opioid Use Disorder

    Not yet reported Eli Lilly and Company 465 participants Est. completion 2028-03 59 sites Stand-alone
    Substance use disorder
    View official trial listing →
  • Recruiting NCT NCT07545759

    A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)

    Not yet reported Eli Lilly and Company 531 participants Est. completion 2027-11 89 sites Stand-alone
    Other conditions: Irritable Bowel Syndrome, Diarrhea
    View official trial listing →
  • Recruiting NCT NCT07545772

    A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)

    Not yet reported Eli Lilly and Company 342 participants Est. completion 2027-09 70 sites Stand-alone
    Other conditions: Irritable Bowel Syndrome, Constipation
    View official trial listing →
  • Recruiting NCT NCT07759245

    A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

    Not yet reported Eli Lilly and Company 606 participants Est. completion 2028-11 127 sites Stand-alone
    Other conditions: Pulmonary Disease, Chronic Obstructive
    View official trial listing →
  • Recruiting NCT NCT07775300

    A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

    Not yet reported Eli Lilly and Company 1000 participants Est. completion 2029-02 169 sites Stand-alone
    Other conditions: Depressive Disorder, Major
    View official trial listing →
  • Completed NCT NCT04648865

    A Study of LY3537031 in Healthy Participants

    Not yet reported Eli Lilly and Company 40 participants Est. completion 2021-06-04 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT06606106

    A Study of LY3537031 in Overweight, Obese, and Healthy Participants

    Not yet reported Eli Lilly and Company 302 participants Est. completion 2026-11 5 sites Stand-alone
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT07165015

    A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

    Not yet reported Eli Lilly and Company 31 participants Est. completion 2026-04-16 4 sites Stand-alone
    Other conditions: Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
    View official trial listing →
  • Completed NCT NCT07202871

    A Study of How the Body Absorbs LY3537031

    Not yet reported Eli Lilly and Company 47 participants Est. completion 2026-07-17 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Active, not recruiting NCT NCT07476118

    A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

    Not yet reported Eli Lilly and Company 150 participants Est. completion 2027-02 3 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Brenipatide, LY3537031

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.